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Losartan modulates muscular capillary density and
reverses thiazide diuretic-exacerbated insulin
resistance in fructose-fed rats
Qi Guo1, Takefumi Mori1, Yue Jiang1, Chunyan Hu1, Yusuke Ohsaki1, Yoshimi Yoneki1, Takashi Nakamichi1,
Susumu Ogawa2, Hiroshi Sato1 and Sadayoshi Ito1
The renin–angiotensin system (RAS) is involved in the pathogenesis of insulin sensitivity (IS). The role of RAS in insulin
resistance and muscular circulation has yet to be elucidated. Therefore, this study sought to determine the mechanisms of
angiotensin II receptor blockers (ARBs) and/or diuretics on IS and capillary density (CD) in fructose-fed rats (FFRs). Sprague-
Dawley rats were fed either normal chow (control group) or fructose-rich chow for 8 weeks. For the last 4 weeks, FFRs were
allocated to four groups: an FFR group and groups treated with the thiazide diuretic hydrochlorothiazide (HCTZ), with the ARB
losartan, or both. IS was evaluated by the euglycemic hyperinsulinemic glucose clamp technique at week 8. In addition, CD in
the extensor digitorum longus muscle was evaluated. Blood pressure was signiﬁcantly higher in the FFRs than in the controls.
HCTZ, losartan and their combination signiﬁcantly lowered blood pressure. IS was signiﬁcantly lower in the FFR group than in
the controls and was even lower in the HCTZ group. Losartan alone or combined with HCTZ signiﬁcantly increased IS. In all
cases, IS was associated with muscular CD, but not with plasma adiponectin or lipids. These results indicate that losartan
reverses HCTZ-exacerbated insulin resistance, which can be mediated through the modulation of muscular circulation in rats
with impaired glucose metabolism.
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INTRODUCTION
Recently, insulin resistance and hyperinsulinemia have been shown to
be common in patients with essential hypertension or metabolic
syndrome.1,2 These impairments of glucose metabolism are associated
with a high risk of cardiovascular diseases, and improving insulin
sensitivity (IS) has become recognized as an important component of
cardiovascular risk reduction in patients with essential hypertension.2,3
Antihypertensive drugs are expected to have a beneﬁcial effect on IS.
It has been consistently shown that angiotensin II receptor blockers
(ARBs) and angiotensin-converting enzyme inhibitors have beneﬁcial
effects on glucose metabolism, whereas the thiazide diuretics have an
adverse effect, resulting in a worsening of IS.4 At the same time, the
results of previous clinical studies examining the effects of ARBs on IS
have been equivocal, with IS variously reported as being improved5 or
unchanged.6 In addition, some recent clinical and animal studies have
reported that the antihypertensive and cardiovascular protective
effects of ARBs are strongly reinforced by concomitant administration
of thiazides.7,8 It would thus be of great interest to determine whether
and how ARBs modulate thiazide diuretic-exacerbated IS in hyperten-
sion and metabolic syndrome.
Skeletal muscle is considered a primary site of insulin resistance in
essential hypertension.9 Euglycemic hyperinsulinemic glucose clamp
studies have demonstrated that skeletal muscle accounts for over 80%
of glucose disposal under hyperinsulinemic conditions in humans.
Insulin-mediated glucose uptake has been shown to be correlated with
capillary density (CD).10 CD in skeletal muscle has been shown to be
decreased in patients with hypertension,11 non-insulin-dependent
diabetes mellitus12 and obesity,13 as well as in experimental animal
models.14–16 It has also been suggested that the diffusion distance from
capillaries to muscle cells and/or some biochemical changes related to
the diffusion distance contribute to a decrease in IS.17
Thus, we hypothesized that an ARB would reverse the thiazide
diuretic-induced decrease in IS by modulating the muscle CD in
hypertension. This study was designed to test this hypothesis by
examining whether a thiazide diuretic (hydrochlorothiazide: HCTZ)
or an ARB (losartan) alters IS in fructose-fed rats (FFRs), and if so,
whether CD in skeletal muscle is involved in such changes. We selected
the FFR model because a high-fructose diet in rats causes metabolic
derangements, including hypertension and insulin resistance.18,19
Similarly, studies have demonstrated that the consumption of high
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METHODS
General protocol
Six-week-old male Sprague-Dawley rats (SLC, Shizuoka, Japan) were housed in
a controlled temperature (241C) room with a 12-h light–dark cycle. All
procedures were in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals, and the protocols were approved
by the Animal Committee of Tohoku University. The rats were divided into two
groups at the start of study: one fed standard chow containing 60% starch, 5%
fat and 21% protein (Oriental Yeast, Tokyo, Japan; control; n¼10) and the
other fed fructose-rich chow containing 60% fructose, 5% fat and 21% protein
(F2HFrD; Oriental Yeast; FFR; n¼33) for 8 weeks. For the last 4 weeks, the
FFRs were allocated to four groups: the FFR group (FFR; n¼9), HCTZ (Merck,
Whitehouse Station, NJ, USA) group (FFR+HCTZ; n¼9), losartan (Merck)
group (FFR+LOS; n¼7) and HCTZ plus losartan group (FFR+HCTZ+LOS;
n¼8). HCTZ dissolved in 0.5% carboxymethylcellulose was administered by
gavage daily at a dose of 80mgkg 1day 1 in the FFR+HCTZ and
FFR+HCTZ+LOS groups. Because one aim of the study was to examine the
effect of losartan on IS exacerbated by HCTZ, we selected the highest dosage of
HCTZ that has been commonly used in other rat studies8,21 to determine the
maximum adverse effect on glucose metabolism. Losartan dissolved in water
was given by gavage daily at a dose of 10mgkg 1day 1 in the FFR+LOS and
FFR+HCTZ+LOS groups. Rats were pair-fed to ensure equivalent caloric
intake, thereby avoiding the inﬂuence of different food volumes on metabolic
abnormalities. Body weight was measured weekly. Systolic blood pressure
(SBP) was measured every week from 6–14 weeks of age in conscious rats by
the indirect tail-cuff method (Model MK-2000A; Muromachi, Tokyo, Japan).
Surgical procedures and drawing blood
At the age of 14 weeks, after an overnight fast and under ether anesthesia, the
rats were implanted with an arterial catheter (PE 100, Becton Dickinson,
Sparks, MD, USA) and venous catheter (PE 20), each ﬁlled with heparinized
saline (100IUml 1), into the left carotid artery and right jugular vein,
respectively. The free ends of these catheters were brought subcutaneously to
the back of the neck. During surgery, a 0.5ml blood sample was collected from
the left carotid artery for biochemical analysis in all rats. Serum triglycerides
were measured by a standard autoanalysis technique (Synchron-CX-3; Beck-
man Coulter, Fullerton, CA, USA). Serum adiponectin levels were measured
using the enzyme-linked immunosorbent assay kit (Otsuka Pharmaceutical,
Tokyo, Japan). The rats were returned to their individual cages and allowed to
recover for 3 days after surgery.
Euglycemic hyperinsulinemic glucose clamp technique
After overnight fasting, conscious rats were examined for IS by a euglycemic
hyperinsulinemic glucose clamp technique, as described previously.22,23 Brieﬂy,
before the start of the glucose clamp, fasting blood glucose was measured by a
blood glucose test meter (A790820; GUNZE, Kyoto, Japan). An initial bolus of
insulin (25mUkg 1 of Humalin R, U-100; Eli Lilly Japan, Kobe, Japan) was
infused through a venous catheter, and this step was followed by a constant
infusion of insulin at a rate of 4mUkg 1min for 147min. During the glucose
clamp, 12.5% glucose solution was infused as required to maintain the blood
glucose at the fasting level. A volume of 10ml samples of arterial blood was
collected through an arterial catheter at 7-min intervals for the determination
of blood glucose. The average rate of glucose infusion (mgkg 1min 1) for the
last 35min was taken as an index of IS (M value).22,23
Tissue preparation and histological examination
After the IS test, the rats were killed by intraperitoneal injection of pentobar-
bital (100mgkg 1). The extensor digitorum longus (EDL) muscle was rapidly
dissected and weighed. Each EDL muscle was sliced transversally in the
midbelly region into 6-mm sections. These samples were rapidly frozen in
isopentane cooled by dry ice and stored at  801C until use. Serial transverse
cross-sections (10mm thick) near the mid-belly portion of the EDL were cut in
a microtome cryostat at  221C, mounted on glass slides and air-dried. CD was
determined by the methods described previously.22 The capillary-to-ﬁber ratio
(C/F) and CD were estimated using an image processing software package
(WinROOF ver. 5.0; Mitani Corporation, Tokyo, Japan). For each muscle, at
least 200 ﬁbers and their associated capillaries were measured using the
maximal number of non-overlapping ﬁelds.
Data analysis
All results are expressed as means±s.e.m. All data analyses were performed by
Bonferroni/Dunn testing for multiple comparisons after one-way analysis of
variance. Pearson’s correlation coefﬁcient and regression analysis were used to
compare the relationship between M values and CD or C/F. To identify
determinants of change in M values, we performed multiple stepwise regression
analysis to compare the relationship between M values as the dependent
variables and ﬁve variables (CD or C/F and SBP, BW, serum adiponectin and
triglycerides) as independent variables. Values of Po0.05 were considered to
indicate statistical signiﬁcance.
RESULTS
Blood pressure
Rats were pair-fed to ensure equivalent caloric intake throughout the
experimental period. However, in the ﬁrst 4 weeks, the food volume in
the control rats was actually greater than that in the FFR groups; thus,
we had to restrict the food volume in the control rats to achieve caloric
equivalence among the groups. However, for the last 4 weeks, the food
volume in the FFR+HCTZ+LOS rats was the smallest among the
groups, such that we had to restrict the food volume in the control,
FFR, FFR+LOS and FFR+HCTZ groups. Therefore, the SBP in FFRs
progressively increased throughout the ﬁrst 4 weeks, but the SBP was
not signiﬁcantly changed during the last 4 weeks in FFRs, as shown in
Figure 1. HCTZ alone, losartan alone, and the two drugs in combina-
tion completely attenuated the development of hypertension after the
4-week treatment. In addition, the SBP in the FFR+HCTZ+LOS rats
at weeks 6, 7 and 8 of the experimental period was lowest among the
ﬁve groups.
Insulin sensitivity
Figure 2 shows the time course of the blood glucose level (upper
panel), insulin infusion rate (middle panel) and glucose infusion rate
(lower panel) of the glucose clamp in each group. Steady-state blood
Figure 1 Sequential systolic blood pressure values during the 8-week
experimental period in the ﬁve groups: control (n¼10), normal diet group;
fructose-fed rat (FFR) (n¼9), fructose-fed rats group; FFR+HCTZ (n¼9),
fructose-fed rats and hydrochlorothiazide group; FFR+LOS (n¼7), fructose-
fed rats and losartan group and FFR+HCTZ+LOS (n¼8), fructose-fed rats
and hydrochlorothiazide plus losartan group. Data are the means±s.e.m.
*Po0.01 vs. control.
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experimental groups. The mean coefﬁcient of variation (%)¼SD/
mean 100) of the plasma glucose level during the clamps in the ﬁve
experimental groups was 3%. The M values in the ﬁve groups are
shown in Figure 3. M values were signiﬁcantly lower in the FFR
groups (11.6±0.9mgkg 1min 1) than in the control group
(16.8±0.7mgkg 1min 1). HCTZ further reduced the M values in
the FFR+HCTZ group (8.5±0.8mgkg 1min 1) to less than those of
the FFR group. However, losartan signiﬁcantly increased the M values
in the FFR+LOS (15.1±0.9mgkg 1min 1) and FFR+HCTZ+LOS
(15.7±0.9mgkg 1min 1) groups compared with those of the FFR
group.
CD and regression analyses
The effects of treatment on C/F and CD are shown in Figure 4. The C/
F and CD in the FFR groups were signiﬁcantly lower than in the
control group. The CD in the FFR+LOS group and the C/F and CD in
the FFR+HCTZ+LOS group were signiﬁcantly higher than those in
the FFR group. Although it did not reach the level of signiﬁcance
(P¼0.12), the C/F tended to be higher in the FFR+LOS group than in
the FFR group. However, the C/F and CD in the FFR+HCTZ group
were signiﬁcantly lower than those in the FFR group (Figure 5).
Figure 2 Time course of blood glucose level (upper panel), insulin infusion
rate (middle panel) and glucose infusion rate (lower panel) of the glucose
clamp in ﬁve groups: control (n¼10), normal diet group; FFR (n¼9),
fructose-fed rats group; FFR+HCTZ (n¼9), fructose-fed rats and
hydrochlorothiazide group; FFR+LOS (n¼7), fructose-fed rats and losartan
group and FFR+HCTZ+LOS (n¼8), fructose-fed rats and hydrochlorothiazide
plus losartan group. Data are the means±s.e.m. *Po0.05 vs. control;
wPo0.05 vs. FFR.
Figure 3 Comparisons of the index of insulin sensitivity (M value) in the ﬁve
groups: control (n¼10), normal diet group; FFR (n¼9), fructose-fed rats
group; FFR+HCTZ (n¼9), fructose-fed rats and hydrochlorothiazide group;
FFR+LOS (n¼7), fructose-fed rats and losartan group and FFR+HCTZ+LOS
(n¼8), fructose-fed rats and hydrochlorothiazide plus losartan group. Data
are the means±s.e.m. *Po0.01 vs. control; wPo0.01 vs. FFR.
Figure 4 Comparisons of the capillary-to-ﬁber ratio (C/F) (a) and capillary
density (CD) (b) in the ﬁve groups: control (n¼10), normal diet group; FFR
(n¼9), fructose-fed rats group; FFR+HCTZ (n¼9), fructose-fed rats and
hydrochlorothiazide group; FFR+LOS (n¼7), fructose-fed rats and losartan
group and FFR+HCTZ+LOS (n¼8), fructose-fed rats and hydrochlorothiazide
plus losartan group. Data are the means±s.e.m. *Po0.01 vs. control;
wPo0.05 vs. FFR.
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and C/F (Figure 6a) and CD (Figure 6b). In addition, we performed
multiple stepwise regression analysis to compare the relationship
between M values as dependent variables, ﬁve variables with CD
(CD, SBP, BW, serum adiponectin and triglycerides) as independent
variables and M values and ﬁve variables with C/F (C/F, SBP, BW,
serum adiponectin and triglycerides), respectively. The data indicated
that the M values were predicted by the CD (R2¼0.35, F¼21.7,
Po0.0001) and C/F (R2¼0.33, F¼20.5, Po0.0001), respectively, but
not by SBP, BW, serum adiponectin or triglycerides, at week 8 in all
rats.
Body weight and serum compositions
There were no signiﬁcant intergroup differences in BW or serum
triglycerides at week 8 (Table 1). The serum adiponectin level in the
FFR groups was signiﬁcantly lower than that in the control group. The
serum adiponectin levels in the FFR+HCTZ and FFR+HCTZ+LOS
groups were signiﬁcantly lower than those in the FFR group. However,
there were no statistically signiﬁcant differences in the serum adipo-
nectin levels between the FFR+HCTZ and FFR+HCTZ+LOS groups
or between the FFR and FFR+LOS groups.
DISCUSSION
This study conﬁrmed previous reports that a fructose-rich diet reduces
IS in normal rats and leads to hypertension.18,19,24 The CD of skeletal
muscle was lower in FFRs than in the controls, and HCTZ further
Table 1 Body weight (BW) and serum triglyceride and adiponectin
levels at week 8 of the experimental period
Groups (n) BW (g)
Serum triglyceride
(mgdl 1)
Serum adiponectin
(mgml  1)
Control (10) 390±76 4 . 6 ±14.6 3.44±0.52
FFR (9) 388±98 6 . 0 ±11.3 2.42±0.18*
FFR+HCTZ (9) 374±99 6 . 0 ±23.6 1.13±0.12*w
FFR+LOS (7) 384±59 5 . 5 ±12.2 2.12±0.23*
FFR+HCTZ+LOS (8) 378±89 7 . 3 ±15.8 1.01±0.08*w
Abbreviations: Control, normal diet group; FFR, fructose-fed rats group; FFR+HCTZ, fructose-fed
rats and hydrochlorothiazide group; FFR+LOS, fructose-fed rats and losartan group;
FFR+HCTZ+LOS, fructose-fed rats and hydrochlorothiazide plus losartan group. Data are the
means±s.e.m.
*Po0.01 vs. control; wPo0.01 vs. FFR.
Figure 5 Representative cross-sections of extensor digitorum longus muscle in the ﬁve groups. The capillaries stained blue. Scale bar 50mm. Control, normal
diet group; FFR, fructose-fed rats group; FFR+HCTZ, fructose-fed rats and hydrochlorothiazide group; FFR+LOS, fructose-fed rats and losartan group and
FFR+HCTZ+LOS, fructose-fed rats and hydrochlorothiazide plus losartan group.
Figure 6 Correlation between M value and capillary-to-ﬁber ratio (C/F) (a)
and capillary density (CD) (b).
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effects. However, treatment with losartan recovered IS and CD in both
the FFR and the FFR+HCTZ groups to the level seen in the control
rats. Multiple regression analysis indicated that the M value, a marker
of IS, was predicted by CD in the EDL independent of SBP, BW and
serum adiponectin and triglycerides in this study. These results
indicate that CD has a role in the modulation of IS by a fructose
diet and HCTZ and/or losartan treatment. To the best of our knowl-
edge, this study is the ﬁrst to investigate CD in FFRs after treatment
with HCTZ and/or losartan.
Effects of thiazide diuretics and ARBs on IS
It has been shown that high doses of thiazide diuretics have an adverse
effect on glucose metabolism. Consistent with the previous study,18
the results in this study demonstrated that HCTZ signiﬁcantly
worsened the fructose-induced decrease in IS in FFRs. Conversely,
the present ﬁndings showed that losartan signiﬁcantly improved IS in
FFRs. Several previous studies failed to demonstrate any losartan-
induced improvement in IS in hypertensive or normotensive sub-
jects6,25 or in type 2 diabetic rats (IS was assessed by oral glucose
tolerance test).26 Moan et al.27 found that losartan improved IS in
patients with severe essential hypertension but had little effect on IS in
those patients with mild essential hypertension. Although our recent
results showed that the ARB olmesartan did not signiﬁcantly improve
(less effect) IS in spontaneously hypertensive rats,22 which was
consistent with our present results, Higashiura et al.28 reported that
olmesartan signiﬁcantly improved IS in FFRs (IS was assessed by the
euglycemic hyperinsulinemic glucose clamp technique). These differ-
ent ﬁndings concerning the effects of ARBs on IS may be related to
differences in the subjects or rat strains, as well as differences in the
measurement methods for IS analysis. In our present and previous
studies, we used the euglycemic hyperinsulinemic clamp technique, a
gold standard method for investigating and quantifying IS, because it
measures the amount of glucose necessary to compensate for an
increased insulin level without causing hypoglycemia.29 This techni-
que is a better evaluation method than other methods, such as the oral
glucose tolerance test. Although the mechanisms by which ARBs
improve IS are not fully understood, a possible mechanism by
which ARBs improve IS is through increased cellular cyclic adenosine
3¢,5¢-monophosphate levels and the production of insulin-like growth
factor-I.30 In addition, losartan might improve IS by activating
insulin-sensitizing peroxisome proliferators-activated receptor
(PPAR)-g.31 However, the ability of other ARBs (such as olmesartan)
to activate PPAR-g receptors tested in this setting was less.32
Capillary density in skeletal muscle is decreased in
insulin-resistant rats
Several reports have shown the relationship between skeletal muscle
CD and IS/resistance in humans.11–13,33–35 Likewise, rodent studies
have demonstrated a direct effect of capillarization on insulin action in
skeletal muscles.14–16,36,37 A decrease in CD is associated with a longer
diffusion distance between the nutritional blood vessels and the
skeletal muscle cells. This change would impede the delivery of glucose
to the muscle cells and thereby decrease IS.17 In this study, there was a
signiﬁcant positive correlation between IS and CD values in the EDL
muscle, and IS was predicted by CD in the EDL independent of SBP,
BW, serum adiponectin and triglycerides in all the rats. Thus, fructose,
HCTZ and losartan affected IS, at least in part by changing the CD.
In this study, CD in the EDLwas signiﬁcantly lower in FFRs than in
the controls. However, Takada et al.19 reported that the CD in the
soleus muscle in FFRs was not altered by fructose-rich chow. The
reason for the disparate results between the previous study and this
study is not clear, but differences in the kind of skeletal muscle
may be involved. Skeletal muscle consists of type I, type IIa and
type IIb ﬁbers. Type I and type IIa ﬁbers have high capillary densities,
whereas type IIb ﬁbers have a low CD.38,39 It is thought that an
increase in type IIb ﬁbers contributes to the reduction in CD. As
reported by Higashiura et al.,28 the percentage of type IIb ﬁbers in the
soleus muscle is o1%, and thus there is no signiﬁcant difference in
the amount of type IIb ﬁbers in the soleus muscle between FFRs
and control rats. However, there are a signiﬁcant decrease in the
percentage of type I ﬁbers and a signiﬁcant increase in the percentage
of type IIa ﬁbers in FFRs relative to controls. The EDL muscle has
more type IIb ﬁbers than the soleus muscle, so it may be easier to
detect differences in CD based on changes in type IIb ﬁbers in the
EDL than in the soleus muscle. Thus, we evaluated CD in the EDL in
this study, and our results showed that a fructose-rich diet in normal
rats reduced CD in the EDL. Similarly, our results showed that the CD
in skeletal muscle decreased in an experimental animal model of
insulin resistance.14–16 Frisbee et al.15 suggested that microvessel
rarefaction in the skeletal muscles of obese Zucker rats manifesting
insulin resistance did not depend on an elevated mean arterial
pressure and that other factors associated with insulin resistance
may underlie the progressive reduction in skeletal muscle microvessel
density in these animals. These results suggest that there is an
association between IS and CD in skeletal muscle, although the
mechanisms are not clearly understood. Ellis et al.16 found that insulin
attenuates the O2-dependent release of adenosine triphosphate from
the red blood cells and suggested that this defect in red blood cell
physiology could contribute to a failure in the regulation of the O2
supply to meet the demand in the EDL in a model of insulin resistance
using diabetic fatty Zucker rats fed a high-fat diet. In addition, a high
fructose diet also causes mitochondrial dysfunction in skeletal mus-
cle,40,41 and mitochondrial dysfunction has been associated with
insulin resistance in skeletal muscle.42 Brownlee suggested that mito-
chondrial dysfunction occurs as a ‘unifying mechanism’ for micro-
vascular and macrovascular complications through reactive oxygen
species production.43 Hyperglycemia induced by endothelial dysfunc-
tion is inhibited by blocking ROS production from mitochondria and
by overexpression of uncoupling proteins or manganese superoxide
dismutase.43 Furthermore, endothelial NO synthase in vascular
endothelial cells seems to have an important role in insulin-stimulated
NO production and vasodilation.44
Mechanisms of thiazide diuretics and ARBs on capillary density in
skeletal muscle
Capillary rarefaction associated with hypertension has been consid-
ered a form of structural autoregulation, reﬂecting the long-term
adaptation of the microcirculation to elevated blood pressure. It has
been shown that vasodilatation and increased blood ﬂow promote
angiogenesis in skeletal muscles.45 Thus, losartan may increase the CD
through its vasodilator action or hypotensive effect.46 In addition to
the vasodilator or hypotensive effect, the proangiogenic effect of
losartan may also be mediated by the following mechanism: ARB
blocks AT1 receptors, whereas unbound angiotensin II stimulates AT2
r e c e p t o r s ,w h i c hi nt u r ni n c r e a s ea n g i o g e n i cf a c t o r s ,s u c ha sv a s c u l a r
endothelial growth factor receptors, Tie-2 expression and the angio-
poietin-1/angiopoietin-2 ratio.47 In addition, You et al.48 reported that
losartan administration resulted in an improvement in hindlimb
ischemia-induced capillary rarefaction, and this improvement was
associated with a restoration of progenitor cell-related function in
spontaneously hypertensive rat. In contrast, although HCTZ and
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with HCTZ decreased the CD, indicating that blood pressure
was not involved in the changes in CD and IS. A possible mechanism
by which HCTZ decreased the CD is that HCTZ reduced blood
pressure through decreased cardiac output,49 and decreased cardiac
output associated with a decreased peripheral blood ﬂow would
contribute to the induction of capillary rarefaction in skeletal mus-
cle.45 Capillary rarefaction would enable the tissue blood ﬂow to be
regulated without consumption of the energy necessary for active
vasoconstriction.14
Serum adiponectin cannot mediate the beneﬁcial effects of
ARBs on IS in FFR
Conversely, consistent with previous reports,50,51 the results in this
study indicated that the decreases in IS induced by a fructose-rich diet
or administration of HCTZ are associated with decreased serum
adiponectin, a protein with levels that are known to increase with
existing PPAR-g agonists and to correlate with IS.52 However, in this
study, losartan-increased IS in the FFR+LOS and FFR+HCTZ+LOS
groups was not coupled with increased serum adiponectin levels.
Recently, several studies, but not all, have revealed that ARBs improved
hypertension with increasing adiponectin.24,51 Consistent with our
present results, Kamari et al.24 reported that telmisartan, an ARB with
greater PPAR-g activity, effectively improved fructose-induced hyper-
tension, hyperinsulinemia and hypertriglyceridemia, but did not affect
serum adiponectin in FFRs. In addition, Sharabi et al.53 showed in
FFRs that the PPAR-g agonist rosiglitazone improved the metabolic
proﬁle to a degree similar to telmisartan, but with increases in serum
adiponectin levels and gene expression. Therefore, it is unlikely that
adiponectin could always mediate the beneﬁcial effects of ARBs on IS
in FFRs.
Pair-feeding can eliminate effects of food volume on BW and
serum triglyceride
IS is negatively correlated with BW. However, the FFR model is
associated with weight loss, although it is a commonly used model
that mimics human metabolic syndrome in many respects, including
hypertension and insulin resistance.19 In addition, food volume can
also inﬂuence glucose, insulin and triglyceride levels. In this study,
therefore, all rats were pair-fed to eliminate these effects related to
food volume. There were no signiﬁcant intergroup differences in BW
or serum triglycerides at week 8 of this study. We therefore concluded
that the intergroup differences in IS were not related to differences in
food volume.
In summary, we have demonstrated that HCTZ decreased IS, but
losartan ameliorated the HCTZ-induced decrease in IS in FFRs, and
these changes in IS were at least partially attributable to a modulation
of CD in skeletal muscles. If these ﬁndings are conﬁrmed in humans,
then the combination of losartan and HCTZ may be recommended
for the treatment of hypertensive subjects with insulin resistance,
without considering the adverse effect of thiazide diuretics on glucose
metabolism.
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